SuperworthNeuraxis, INC EPS NRXS
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$0.79
- Latest quarter, Q2 FY26
- −$0.19
- Fiscal year 2025
- −$0.97
Neuraxis, INC's earnings per share was −$0.79 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.19.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.97 | n/a |
| FY2024 | −$1.21 | n/a |
| FY2023 | −$5.07 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.19 | n/a | −$0.79 | |
| Q1 FY26 | −$0.18 | n/a | −$0.82 | |
| Q4 FY25 | −$0.18 | n/a | −$0.97 | |
| Q3 FY25 | −$0.24 | n/a | −$1.01 | |
| Q2 FY25 | −$0.22 | n/a | −$1.02 | |
| Q1 FY25 | −$0.33 | n/a | −$1.22 | |
| Q4 FY24 | −$0.22 | n/a | −$1.21 | |
| Q3 FY24 | −$0.25 | n/a | −$1.29 | |
| Q2 FY24 | −$0.42 | n/a | −$3.42 | |
| Q1 FY24 | −$0.32 | n/a | −$4.21 | |
| Q4 FY23 | −$0.30 | n/a | −$5.07 | |
| Q3 FY23 | −$2.38 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Neuraxis, INC's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NRXSNeuraxis, INC | −$0.79 | |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| Peer median | $0.41 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Neuraxis, INC
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.